Cellular Intelligence Names Single-Cell Biology Pioneer Arjun Raj, Ph.D., Chief Scientific Officer and Scientific Co-Founder

Renowned University of Pennsylvania professor takes on expanded leadership role to advance the company's science and scale its closed-loop cell signaling platform.

BOSTON, Aug. 12, 2026 /PRNewswire/ -- Cellular Intelligence, the AI company building a universal foundation model of cell signaling, today announced that Arjun Raj, Ph.D., has been appointed chief scientific officer and named scientific co-founder. Raj joined the company full-time in 2025 as head of computational biology while on leave from the University of Pennsylvania. Combining a background in mathematics and systems biology, Raj spent his first year architecting Cellular Intelligence's data engine and scientific program. He has now extended his leave and expanded his mandate to lead overall scientific strategy.

Naming Raj scientific co-founder recognizes the foundational role he has played at the company, from the design of its experiments and data generation methodologies to the development and validation of its models. As chief scientific officer, he will lead the integration of experimental biology, computational biology, machine learning, and translational science into a closed-loop system built to understand, predict, and ultimately control cell behavior.

"Arjun joined us because he saw the possibility of building something biology has never had: massive, context-rich, time-resolved perturbation datasets, and models purpose-built to learn from them. In his first year at the company, he helped turn that possibility into reality," said Micha Breakstone, Ph.D., co-founder and chief executive officer of Cellular Intelligence. "Arjun moves fluently between machine learning and experimental biology while remaining deeply grounded in fundamental science. Naming him scientific co-founder recognizes the company he has already helped build. As chief scientific officer, he will lead our efforts to scale the foundation model and unlock a new era of predictable cell engineering."

Cellular Intelligence has developed a proprietary capsule-based platform that runs time-varying, sequential signaling combinations in parallel within a single experiment, expanding the scale of controlled perturbation experimentation by orders of magnitude. Rather than relying on static observations collected for other purposes, the company designs controlled, intervention-rich experiments that reveal how cells respond as signals, timing, and context change. The resulting data train models that identify gaps in their own understanding, guide the next generation of experiments, and improve with every cycle.

"I have spent my career trying to understand how individual cells make decisions, and what has always limited the field is the data," said Arjun Raj, scientific co-founder and chief scientific officer of Cellular Intelligence. "Cellular Intelligence is building high-fidelity, time-resolved perturbation data generated expressly for learning. For the first time, I can see a path from observing cellular decisions to predicting and eventually controlling them."

Raj is the Richard K. Lubin Professor of Bioengineering and Professor of Genetics at the University of Pennsylvania. A mathematician turned experimental systems biologist, he co-developed a foundational method for visualizing and counting individual RNA molecules inside single cells. His lab has since made influential contributions to understanding stochastic gene expression, cell identity, rare non-genetic states in cancer therapy resistance, and cellular memory. He received his bachelor's degree in physics and mathematics from the University of California, Berkeley, and his doctorate in mathematics from the Courant Institute at New York University. He completed postdoctoral training at the Massachusetts Institute of Technology and joined Penn's faculty in 2010.

Raj's expanded role comes as Cellular Intelligence connects its foundation-model platform to a direct path to patients. In May, the company acquired STEM-PD, an investigational Phase 2-ready Parkinson's disease cell therapy program, from Novo Nordisk. STEM-PD is both a therapy the company is working to advance for patients and a proving ground for the company's technology, in which models help sharpen protocol optimization, manufacturing scalability, comparability, potency, and dosing, and in which clinical and manufacturing insights flow back into those models. The result is a continuous learning system—described in a recent white paper, "From Model to Medicine - and Back"—in which better science aims to yield a better therapy, and the therapy in turn strengthens the science.

To learn more, visit www.cellularintelligence.com.

About Cellular Intelligence
Cellular Intelligence is building a universal foundation model for cell signaling to understand, predict, and ultimately control how cells behave, transforming biology from trial and error into an engineering discipline. A clinical-stage AI company, Cellular Intelligence holds the global rights to STEM-PD, an investigational Phase 2-ready cell therapy for Parkinson's disease with FDA Fast Track designation, acquired from Novo Nordisk. The company's founding team includes repeat AI entrepreneur Dr. Micha Breakstone (Chorus.ai, acquired for $575M), the Head of the Fundamental AI Group at MIT, and five professors from Harvard Medical School, the University of Pennsylvania, and the University of Washington, collectively holding five National Academy memberships. Based in Boston, Cellular Intelligence has raised over $70M from Khosla Ventures, the Chan Zuckerberg Initiative, Novo Nordisk, AMD Ventures, and others.

STEM-PD is an investigational therapy. Its safety and efficacy have not been established.

Contact: [email protected] 

SOURCE Cellular Intelligence